The international survey on the management of allergic rhinitis by physicians and patients (ISMAR)

Carlos E Baena-Cagnani1†, Giorgio W Canonica2*, Mohamed Zaky Helal3†, René Maximiliano Gómez4†, Enrico Compalati2†, Mario E Zernotti5†, Mario Sanchez-Borges6†, Fabio F Morato Castro7†, Margarita Murrieta Aguttes8†, Aida López-Garcia9†, Faheem A Tadros10† and ISMAR Study Group

Abstract

Epidemiologic studies suggest that the prevalence of allergic rhinitis (AR) is rising worldwide. Several reports, in fact, indicate increasing trends in the prevalence of AR especially in developing countries, likely related to the environment and climate changes and the adoption of an urbanized Western lifestyle. The primary objective of the present study was to collect information about management in real-life settings, including a characterization of typical patients’ profile referring to physicians, the disease features, the common approaches to diagnostic assessments and therapeutic decisions. This was an international, multicenter, cross-sectional study conducted in adults or children (≥6 years) suffering from rhinitis confirmed by physician’s diagnosis for at least one year. The 234 physicians who participated in the study included a total of 2778 patients in Egypt, Mexico, Brazil, Colombia, Guatemala, Iran, Venezuela, Argentina, Israel, Kuwait and United Arab Emirates. It was found that clinical history was the selected tool to diagnose and categorize AR patients (97.1%), with less than half of patients undergoing allergy testing, may be explaining the scarce use of immunotherapy on management of disease. Out of 2776 patients, 93.4% had somehow received a recommendation to avoid allergens and irritant agent exposure. Notably, 91.4% were receiving at least one treatment at the time of the survey, mostly oral antihistamines (79.7%) and intranasal corticosteroids (66.3%). Oral antihistamines, intranasal steroids and decongestants were considered both safe and effective by patients and physicians, preferring oral and nasal route of administration. The ISMAR registry was designed according to the most accepted epidemiological recommendations, and provides interesting information regarding the management of rhinitis from a patient and physician points of view, with many similarities between the participating countries. Further efforts are required to better manage AR and its comorbidities.

Background

Epidemiologic studies suggest that the prevalence of allergic rhinitis (AR) is rising worldwide; 400 million of people suffer from rhinitis [1].

The cause of this increase is unknown, although some contributing factors include high concentrations of airborne allergens and pollution, less ventilation indoors, dietary factors, smoking and more sedentary lifestyles, among others. Several reports indicate trends in AR prevalence especially in developing countries, likely related to the environment and climate changes and the adoption of an urbanized Western lifestyle [2].

SIDRIA (Italian Studies on Respiratory Disorders in Children and the Environment) studies designed to fill the gap in knowledge regarding time trends of prevalence of asthma and allergic rhinitis in Italy indicated no changes in the prevalence rates of wheeze and increase in those of rhinitis and eczema among Italian children. The results of this study support the view that profound modifications in the epidemiological features of asthma and allergic diseases are occurring worldwide requiring comprehensive, continuous, epidemiologic monitoring [3].
AR is widely recognized as a public health concern. A recent survey remarked the direct impact of disease on social life, including mood changes, anxiety, depression, and impairment of cognitive function and quality of life [4].

Compared to the general population, people with AR complain more about sleep disturbance difficulty getting to sleep, waking up during the night as a result of their nasal symptoms. The increased risks of obstructive sleep apnea and resulting daytime fatigue have repercussion on working and school performances. It was estimated that in the USA about 3 million working days and 2 million school days lost per year are ascribable to AR, with estimated direct costs of between 2.1 and 5.9 billion US dollars per year [4,5,6]. Estimated productivity drops by an average of 20% on days when nasal symptoms are at their worst [4].

In a study conducted in Denmark the total annual treatment cost of AR is calculated to range between 2,784 and 16,408 DKK per patient [7].

The substantial burden of AR has prompted the international scientific community to develop international guidelines aimed at improving the disease management. ARIA (Allergic Rhinitis and its Impact on Asthma), for instance, is an evidence-based guideline developed in collaboration with the WHO for physicians and healthcare providers, stressing the well characterized links between asthma and rhinitis and providing guidance for their prevention and treatment [8].

Although guidelines provide recommendations about the best management options for most patients in most situations, morbidity of rhinitis is still high and the goal of the treatment is frequently far from being reached. This is likely due to difficulties in the phase of guidelines implementation, influenced by the characteristics of guidelines themselves, social, organizational, economic and political context and the implementation strategies [9]. The under-appreciation of the diseases represents another barrier [8,10]. Being often considered trivial, AR results under-diagnosed and undertreated as a consequence of the fact that only a small proportion of patients visit a specialist [10].

Recent surveys show that patients with AR are not satisfied with their current treatment and this may be a reason of the frequent non-adherence to therapy [9,11,12]. Despite the vast availability of treatment options, 60% of patients are “very interested” in finding a new medication and 25% are “constantly” trying different medications to find one that “works”. Some patients feel their healthcare provider does not understand their allergy treatment needs and does not take their allergy symptoms seriously [11].

The primary objective of the ISMAR study was to collect information about management in real-life settings, including a characterization of typical patients’ profile referring to physicians, the disease features, the common approaches to diagnostic assessments and therapeutic decisions. Moreover, the study was intended to draw a snapshot of the national and local peculiarities of this management and to estimate the relative prevalence of each type of rhinitis in each participating country.

Materials and methods
Study design and population
This was an international, multicenter, cross-sectional study conducted in children (≥6 years) and adults suffering from rhinitis confirmed by physician’s diagnosis for at least one year.

As this was a non-interventional study no allergen skin tests were required during the cross-sectional visit, albeit available information from patients’ records was recorded.

A sample of physicians was selected at random from a master list provided by each country to enter the survey. They included at least 4 physicians (2 private and 2 public practitioners) for each of the following specialties: GPs/family practitioners/internists, allergists/pulmonologists, pediatricians and ENT specialists.

Each physician was allowed to have 10 (and not more than 15) patients participating in the study. To enter the study they should have fulfilled the following inclusion criteria: male or female, adults or children (≥6 years), with rhinitis diagnosed by a physician at least one year before the survey; outpatients visiting their physician for whatever reason, with referred existence of nasal symptoms at any time. Patients participating in any clinical trial or with inability to complete the questionnaire were excluded. The number of interviewed physicians was determined to guarantee statistical significance but, globally and by country, a minimum of 200 patients by country or region had to be included. A maximum number of centers was not defined in the protocol. 234 centers were included in the study in 11 countries, 20 in Argentina, 27 in Brazil, 18 in Colombia, 47 in Egypt, 16 in Guatemala, 17 in Israel, 15 in Iran, 10 in Kuwait, 36 in Mexico, 19 in Venezuela and, 9 in the United Arab Emirates (UAE). Each selected Investigator has to include consecutive patients who meet inclusion criteria.

The study data collection was performed during one single visit.

Data were obtained through 3 types of documents: “Investigator’s Questionnaire”, “Case Report Form” and “Patient’s Questionnaire”.

In the Investigator’s Questionnaire the following data were recorded: the physician profile (age, gender, specialty, years of practising, center location, main workplace), the number of patients with rhinitis seen per week (percentage of these patients with asthma), how they conducted AR diagnosis (key symptoms for diagnosis, complementary methods for diagnosis, severity criteria, categorization of patients), treatment prescribed, knowledge of ARIA, GINA
and other guidelines, patient compliance, personal evaluation of efficacy and safety of main rhinitis treatments, evaluation of patient Quality of Life (if any).

In the Case Report Form the following were recorded: visit date, informed consent, inclusion/exclusion criteria, demographics (date of birth, gender, ethnicity), physical examination data (height, weight), smoking status, relevant medical history, data on the rhinitis diagnosis (year(s) since diagnosis, key symptoms, complementary methods, symptoms and management of rhinitis, co-morbidities [conjunctivitis, sinusitis, otitis media, nasal polyps, asthma (including hospitalization for asthma)].

In the Patient’s Questionnaire, the following data were collected: patient profile (age, gender, current occupation, location), years since diagnosis of rhinitis, smoking status, type of rhinitis, associated symptoms/pathologies, complementary methods for diagnosis, allergens/factors inducing nasal symptoms, preferred drug for nasal symptoms treatment, attitude to prescription, prescription compliance, preferred administration route, and information on patient’s education about rhinitis.

All procedures were performed in accordance with the ethical principles of the Helsinki declaration, with Good Epidemiological Practice guidelines and with the national regulations in force including data protection. The study was approved by the Ethics Committees in accordance with local regulations. Informed consent was obtained prior to any study procedure in order to use patients’ responses in public in an anonymous and confidential way.

Results
Physician population
The 234 physicians who participated in the study had a median age of 49 years, were mainly males with an average experience of 20 years of clinical practice. Demographic characteristics are summarized in Table 1. The most frequent specialty was allergy/pulmonology (35.9%), followed by ENT (30.3%), family practice/internal medicine (22.2%), pediatrics (11.1%). Most of them were private professionals only (41.9%) or with a mixed activity in private and public setting (41.5%); 16.7% was under full regimen of public health system. They were mainly resident in urban area (88.2%) and included a total of 2778 patients.

Data on physicians’ practice
Concerning the regimen of activity, in average 20 patients with rhinitis and 7 with associated asthma were seen weekly.

Most physicians were aware of the existence of international guidelines; 82.5% and 71.4% of them acknowledged ARIA and GINA, respectively, but 56.4% knew also other guidelines, overall recognizing their relevance for categorizing patients in 84.2% and for determining the optimal treatment in 84.6% of cases (Figure 1).

In this study the use of any quality of life (QoL) questionnaire was not a common practice (27.8%). Physicians reported to use the Juniper (35.4%) and the SF-36 (15.4%) questionnaires. Some physicians reported to use them frequently (20%), recurrently (38.5%), or sometimes (41.5%). Their usefulness on treatment decision was judged positively “many times”, “sometimes” or “always” by 47.7%, 15.4% and 35.4% of physicians, respectively (Figure 2).

Rhinitis has been shown to affect the quality of sleep. We observed that a high percentage of physicians (89.7%) usually assessed this outcome, mainly through a clinical history (97.1%). Polysomnography, the Epworth somnolence scale, or other tools were also used by 24.8%, 11.9% and 7.6% of physicians.

The majority of physicians (94.4%) categorized patients according to the clinical history. They preferably adopted a classification based on the severity (80.8%) and the seasonal occurrence of clinical symptoms (59.8%), however 31.2% of them used other criteria based on complementary methods. The assessment of symptoms severity was mainly based on the clinical history (98%). Although some doctors used also QoL questionnaires (38.5%), visual analogue scales (14%), numeric scales or other instruments (11%).

Table 1 Physicians’ demographics and characteristics

| Physicians (234) |
|------------------|
| Age, median (range) | 49 (28–69) |
| Gender, male n (%) | 180 (76.9) |
| Years in practice, median (range) | 20 (1–41) |
| Place of residence, n (%) |
| Urban | 230 (98.7) |
| Suburban | 0 (0) |
| Rural | 3 (1.3) |
| Specialty, n (%) |
| GP/internist | 52 (22.2) |
| Allergist/pneumologist | 84 (35.9) |
| Pediatrician | 26 (11.1) |
| ENT | 71 (30.3) |
| Other | 1 (0.4) |
| Activity setting, n (%) |
| Public | 39 (16.7) |
| Private | 98 (41.9) |
| Mixed | 97 (41.5) |
| Working regimen, Median (range) |
| No. of patients with rhinitis/week | 20 (1–180) |
| No. of patients with asthma among patients with rhinitis | 7 (0–90) |
The most frequent reasons leading to a treatment prescription were related to the severity of symptoms (97.9%), followed by trust in clinical efficacy and safety of drugs (85.9% and 76.5%, respectively). Other reasons, ranging from 65% to 47.9% included personal experience, cost, and frequency of drug intakes, administration route, patients’ requests and categorization.

As suggested by guidelines, oral antihistamines and nasal corticosteroids were the most frequently prescribed drugs. Next in the list were oral decongestants, combinations of antihistamines and decongestants, leukotriene receptor antagonists, whereas topical antihistamines and decongestants, oral and intramuscular steroids, combinations of antihistamines and steroids were the least used drugs. Topical cromones, anticholinergic drugs, allergenspecific immunotherapy and alternative medicines were almost not used (Table 2).

As expected, intranasal corticosteroids (INCs) were reported by physicians as the most effective drugs (extremely effective); while oral antihistamines were considered as the most well tolerated drugs (totally safe). On the other hand, INCs were considered safe and a-H1 as effective as oral corticosteroids. Oral decongestants alone or combined with antihistamines, anti-leukotrienes, intranasal decongestants, intramuscular steroids, and combinations of antihistamines plus steroid were considered equally effective. A similar safety profile was attributed to corticosteroids when administered orally, by intramuscular route or in combination with antihistamines, whereas topical antihistamines were also considered well tolerated but with reduced efficacy (Table 2).
Table 2 Treatment characteristics and scores

| Treatment (score) | Rhinitis treatment frequency reported by physicians, median (0 = not used; 5 = most used) |
|-------------------|----------------------------------------------------------------------------------------|
|                   | Oral anti-histamines (5)                                                                 |
|                   | Intranasal corticosteroids (5)                                                            |
|                   | Oral decongestants (2)                                                                   |
|                   | Antihistamines + decongestants (2)                                                       |
|                   | Leukotriene antagonists (2)                                                               |
|                   | Topical antihistamines (1)                                                                |
|                   | Intranasal decongestants (1)                                                             |
|                   | Oral corticosteroids (1)                                                                  |
|                   | Intramuscular corticosteroids (1)                                                         |
|                   | Antihistamines + steroids (1)                                                             |
|                   | Topical antihistamines (1)                                                                |
|                   | Intranasal decongestants (1)                                                             |
|                   | Oral corticosteroids (1)                                                                  |
|                   | Antihistamines + steroids (1)                                                             |
|                   | Nasal or ocular cromones (0)                                                              |
|                   | Anticholinergic drugs (0)                                                                 |
|                   | Allergen s.c. immunotherapy (0)                                                           |
|                   | Allergen s.c. immunotherapy (0)                                                           |
|                   | Other immunotherapy (0)                                                                  |
|                   | Alternative medicines (0)                                                                 |

| Treatment evaluation by physicians, median (1 = not effective; totally unsafe; 5 = extremely effective; totally safe) |
|---------------------------------------------------------------------------------------------------------------------|
| Efficacy | Safety |
|-----------|--------|
| Oral antihistamines | 4  | 5  |
| Intranasal corticosteroids | 5  | 4.5 |
| Oral decongestants | 3  | 3  |
| Antihistamines + decongestants | 3  | 3  |
| Leukotriene antagonists | 3  | 4  |
| Topical antihistamines | 1  | 3  |
| Intranasal decongestants | 3  | 2  |
| Oral corticosteroids | 4  | 2  |
| Intramuscular corticosteroids | 3  | 2  |
| Antihistamines + steroids | 3  | 2  |

| Judgments about compliance, N (%) | Patient (2776) | Physician (234) |
|----------------------------------|----------------|-----------------|
| Excellent                        | 866 (31.2)     | 18 (7.7)        |
| Very good                        | 825 (29.7)     | 87 (37.2)       |
| Good                             | 633 (22.8)     | 98 (41.9)       |
| Intermediate                     | 297 (10.7)     | 25 (10.7)       |
| Very poor                        | 25 (1)         | 0 (0.0)         |
| Poor                             | 95 (3.4)       | 6 (2.6)         |
| Negative                         | 20 (0.7)       | 0 (0.0)         |
| Unknown                          | 15 (0.5)       | 0 (0.0)         |

| Factors affecting treatment compliance N (%) (AEs = adverse events) | Patient (2776) | Physician (234) |
|---------------------------------------------------------------------|----------------|-----------------|
| AEs produced by medications                                         | 541 (19.5)     | 76 (32.5)       |
| Fear of AEs reported                                                | 503 (18.1)     | 107 (45.7)      |
| Route of administration                                             | 537 (19.3)     | 59 (25.2)       |
| Frequency of doses                                                  | 935 (33.7)     | 91 (38.9)       |
| Efficacy of ongoing treatment                                       | 689 (24.8)     | 84 (35.9)       |
| Cost of medication                                                 | 895 (32.2)     | 165 (70.5)      |
| Taste                                                               | 336 (12.1)     | -               |
| Others                                                              | 399 (14.4)     | -               |

| Patients who received educational information N (%)                  |                |                 |
|----------------------------------------------------------------------|----------------|-----------------|
| Written indication                                                   | 1426 (51.4)    |                 |
| Oral explanations about disease                                      | 2364 (85.2)    |                 |
| Treatment                                                            | 2236 (80.6)    |                 |
| Medication side effects                                              | 1614 (58.1)    |                 |
| Other aspects                                                        | 586 (21.1)     |                 |

s.c.: subcutaneous.
Data on Patients Population

A total of 2778 patients were included in the participating countries. Egypt, Mexico and Brazil included the higher number (45%). The remaining was equally distributed in Colombia, Guatemala, Iran, Venezuela, Argentina, Israel, Kuwait and UAE. 2776 met inclusion criteria and were included in the analysis.

Patients’ characteristics are described in Table 3.

The median age of the included population was 29 years old (range 5–94 years) with males and females equally distributed. They were Latin-Americans (32%), Caucasians (31.1%), Middle-oriental (28.5%), Asian (3.6%) and, others 135 (5.93). Concerning working activity at the time of the survey, most patients were active (25%) and housewives (12%). Considering that about 40% (mainly in the 668 patients under 18 years old) declared other unspecified occupation, remaining people were self-employed, skilled labor, general labor, in business affairs, in pension, or affected by disability and under social security allowance. They were mainly urban area residents (93%).

Concerning the patients’ smoking status, 81.6% had never smoked, 10.3% were former smokers and 8.1% were current smokers. History of any respiratory disease in the course of their life was reported by 43.9% of patients; in particular 47.4% had a history of allergy and 46.5% of ENT conditions (Table 3).

Data on disease characteristics

In this survey, the ARIA classification based on the duration and impact of the disease was the dominant approach in clinical practice, with persistent and intermittent rhinitis identified in 33.4% and 30.7% of cases respectively. However, the previous classification based on symptoms seasonality appeared still adopted: seasonal allergic rhinitis was diagnosed in 27% and perennial allergic rhinitis in 15.1%. The severity of symptoms was mild to moderate in a high percentage (45.4% and 37.3% respectively); only 12.9% of patients judged them as severe. Regarding frequency, most symptoms were present less than 4 days a week (31%). Patients suffering more than 4 days a week were 25.3%. Those suffering more or less than 4 consecutive weeks were 23.3% and 16.4%, respectively (Table 4).

Nasal congestion was the most bothersome symptom motivating the physician visits (84.8%), followed by sneezing (79.1%), anterior rhinorrhea (75.9%) and nasal itching (69.7%).

Patients attributed the onset of symptoms to indoor house dust mites exposure in 84.3% of cases, but also to molds (32.6%), pet dander (30.7%) and pollens were identified as possible causes among outdoor exposure in 40.6% of cases. Other possible allergens were food (18.4%), drugs (8.2%) and latex (6.1%), and not specific factors, like climate changes (81.1%), pollutants (51.2%) and infections (27.9%).

| Table 3 Patients’ demographics and characteristics (N = 2776) |
|--------------------------|----------|
| Age, median (range)      | 29 [5–94] |
| Gender, female n (%)     | 1510 (54.4) |
| Ethnicity                | n (%)    |
| Native Latin-America     | 888 (32.0) |
| Caucasian                | 863 (31.1) |
| Oriental, Arab, Persian  | 791 (28.5) |
| Asian                    | 99 (3.6)  |
| Others                   | 135 (5.93) |
| Place of residence       | n (%)    |
| Urban                    | 2390 (86.1) |
| Suburban                 | 182 (6.6)  |
| Rural                    | 138 (5.1)  |
| Country                  | n        |
| Egypt                    | 500      |
| Mexico                   | 418      |
| Brazil                   | 351      |
| Colombia                 | 223      |
| Guatemala                | 216      |
| Iran                     | 207      |
| Venezuela                | 201      |
| Argentina                | 200      |
| Israel                   | 176      |
| Kuwait                   | 150      |
| UAE                      | 134      |
| Occupation               | n (%)    |
| Professional             | 693 (25.0) |
| Housewife                | 334 (12.0) |
| Self-employed            | 164 (5.9)  |
| Skilled labor            | 141 (5.1)  |
| General labor            | 110 (4.0)  |
| Business                 | 101 (3.6)  |
| Retired                  | 93 (3.4)   |
| Farmer                   | 10 (0.4)   |
| Disability               | 10 (0.4)   |
| Other                    | 1071 (38.6) |
| Missing                  | 49 (1.8)   |
| Smoking status, n (%)    |          |
| Never                    | 2265 (81.6) |
| Former                   | 286 (10.3) |
| Current                  | 225 (8.1)  |
| Medical History, n (%)   |          |
| Respiratory disease      | 1219 (43.9) |
| Allergy                  | 1315 (47.4) |
| ENT disease              | 1292 (46.5) |
Table 4 Disease characteristics

| Type of rhinitis, n (%)                      | Persistent 926 (33.4) | Intermittent 853 (30.7) |
|--------------------------------------------|------------------------|-------------------------|
| Seasonal 748 (27.0)                        |                        |                         |
| Perennial 419 (15.1)                       |                        |                         |

| Key Rhinitis Symptoms for Physician Diagnosis, n (%) |
|-----------------------------------------------------|
| Nasal congestion 2355 (84.8)                        |
| Sneeze 2195 (79.1)                                  |
| Rhinorrhea 2106 (75.9)                              |
| Itching 1935 (69.7)                                 |

| Main nasal symptom according to patients, n (%)     |
|-----------------------------------------------------|
| Nasal blockage 2331 (84)                            |
| Sneeze 2221 (80)                                    |
| Nasal discharge 2101 (76)                           |
| Itching 1855 (67)                                   |

| Intensity of symptoms according to patients, n (%)  |
|-----------------------------------------------------|
| Severe 357 (12.9)                                   |
| Mild 1035 (37.3)                                    |
| Absent 123 (4.4)                                    |

| Frequency of symptoms, n (%)<sup>a</sup> |
|------------------------------------------|
| <4 days/week: 850 (30.6%)                | >4 days/week: 702 (25.3%)               |
| <4 consecutive weeks: 456 (16.4%)       | >4 consecutive weeks: 646 (23.3%)      |

| Causes of symptoms according to patients, n (%) |
|-----------------------------------------------|
| Outdoor:                                      |
| - pollens 1126 (40.6)                        |
| - climate changes 2252 (81.1)                |
| Indoor:                                       |
| - mites 2339 (84.3)                          |
| - infections 775 (27.9)                      |
| - moulds 905 (32.6)                          |
| - dander 851 (30.7)                          |
| - food 511 (18.4)                            |
| - drugs 227 (8.2)                            |
| - latex 168 (6.1)                            |

| Sensitizations documented by skin test, n (%) |
|----------------------------------------------|
| House dust mites 892 (82.9)                  |
| Pollens 506 (47%)                            |
| Moulds 312 (29)                              |
| Other 253 (23.5)                             |
| Pets dander 301 (28.0)                       |

| Co-morbidities, n (%)                        |
|----------------------------------------------|
| Sinusitis 1384 (49.9)                        |
| Otitis media 363 (13.1)                      |
| Asthma 907 (32.7)                            |
| Nasal polyps 310 (11.2)                      |
| Conjunctivitis 1005 (36.2)                   |

| Respiratory symptoms within the last 12 months according to patients, n (%) |
|---------------------------------------------------------------------------|
| Cough | Wheezing | Dyspnea | Chest tightness |
| Recurrent | 1244 (44.8) | 764 (27.5) | 857 (30.9) | 535 (19.3) |
| Nocturnal | 1084 (39.1) | 695 (25.0) | 783 (28.2) | 436 (15.7) |
| Post-exercise | 894 (32.2) | 731 (26.3) | 954 (34.4) | 630 (22.7) |

<sup>a</sup> Missing data: 122 (4.39%).

Patients’ QoL, sleep, mood and physical activities appeared particularly altered in 61.2%, 59.9%, and 49% of cases, respectively, followed by social activities (38%), labor (34.8%), school (19.8%) performances and, personal relationships (31.4%) (Figure 3).

Sinusitis and conjunctivitis were frequent past or current co-morbidities in 49.9% and 36.2% of patients respectively. The coexistence of otitis media (13.1%) and nasal polyposis (11.2%) was less frequent.

Asthma was present in 32.7% and hospitalization for exacerbations within the last 12 months was reported by 12.9% of patients. When surveyed on the frequency of respiratory symptoms in the last year, 44.8% of patients described cough as recurrent, 39.1% as nocturnal and 32.2% following exercise. For wheezing the percentages were 27.5%, 25% and 26.3% respectively. Dyspnea occurred recurrently in 30.9% of patients, during the night in 28.2% and after exercise in 34.4%. Chest tightness was the less perceived symptom, occurring mainly as exercise-induced (22.7%), recurrently in 19.3%, and during the night in 15.2%.

The median number of years before rhinitis diagnosis was 6, ranging from 1 up to 62. Patients reported that the clinical diagnosis was frequently confirmed by additional procedures, like physical examination (95%), radiology (45%) and CT-scan (29%). Among nasal tests, endoscopy was frequently used (27.6%), followed by nasal cytology, biopsy or nasal culture (8.4%), nasal air flow measurement (2.3%), allergen specific nasal challenge (1.6%) and mucociliary test (0.7%). Information regarding the allergic status was obtained from skin tests (38.8%), serum eosinophilia (22.6%), total (21.1%) and specific (5.2%) serum IgE levels.

Skin tests were positive to house dust mites in 82.9% from 1076 patients (38.8% of the whole population), followed by pollens (47%), molds (29%), animal dander (28%), or other allergens (23.5%). Data on disease characteristics are summarized in Table 4.
Data from patients’ on disease management

Out of 2776 patients, 93.4% (2592) had somehow received a recommendation to avoid allergens and irritant agent exposure. Notably, 2537 (91.4%) were receiving at least one treatment at the time of the survey, mostly oral antihistamines (79.7%) and intranasal corticosteroids (66.3%) (Figure 4).

Less prescribed were oral (24.7%) or topical decongestants (26.5%), leukotriene antagonists (16.4%), allergen specific subcutaneous immunotherapy (14.2%), oral steroids (13.3%), topical antihistamines (12.6%) or sublingual immunotherapy (3.1).

Oral antihistamines and topical steroids were preferred by 75.9% and 49.2% of patients, respectively, followed by topical (33.4%) and oral (29.3%) decongestants, topical antihistamines (13.3%), allergen immunotherapy (11.8%), leukotriene antagonists (9.9%), and oral steroids (8.4%). Oral and intranasal routes of administration (60.3% and 32.4%, respectively) were preferred to the injectable (6.2%) or others administration routes (1.1%) (Figure 5).

When patients’ and doctors’ judgments on treatment compliance were compared, different viewpoints leap out. According to patients, compliance was excellent (31.2%), very good (29.7%) and good (22.8%), which was different from the physicians’ point of view (7.7%, 37.2% and 41.9%, respectively). Very few patients (from 3 to 10%) judged it as poor or unsatisfactory (Table 4).
A different weight was attributed by the two counterparts to the factors affecting the treatment compliance. According to physicians, the drugs cost was the most important conditioning factor (70.5%), followed by the fear of reported adverse events (45.7%), the need for frequent doses (38.9%), the efficacy of ongoing treatment (35.9%), the occurrence of drug-related adverse events (32.5%) and the route of administration (25.2%). Conversely, patients referred to be mainly bothered by the need of frequent doses (33.7%) and the cost of medications ranked in second position (32.9%). Patient did not appear particularly worried by the fear of reported (18.1%) or drug related (19.5%) adverse events. On the other hand, some patients considered the current ongoing therapy efficacy (24.8%) and the route of administration (19.3%) as a cause affecting the compliance (Table 4).

Finally, when patients were asked if they have received any kind of education for the management of their condition, a written set of indications was referred to by 51.4% of them. Most patients received oral explanations about the characteristics of their disease (85.2%) and its treatment (80.6%); only 58.1% received information about side effects or other aspects (21.1%).

**Peculiarities in different areas**

The included population mean age ranked between 22 and 27 years old in all participant countries.

No significant differences were observed in terms of management and guidelines implementation between the different Latin-American countries. Differences were observed in the frequency of the different comorbidities, the frequency of sinusitis was higher in Argentina (62%) and Guatemala (57%), compared to the other countries. The frequency of asthma varied between 28% in Mexico and 46% in Brazil. In addition, the use of skin tests to detect the main allergen provoking the rhinitis varied between the countries and ranks from 24 to 60%.

In Middle–East countries, no significant differences were observed in terms of management even if the implementation of guidelines was lower than in Latin American countries.

The use of skin testing to identify the type of allergen was very low compared to the Latin American countries ranging from 9 to 29%. In terms of comorbidities, the frequency of sinusitis ranged from 34% in Israel to 61% in Iran. Asthma frequency appeared lower than in Latin America varying between 18% in UAE to 37% in Egypt.

**Discussion**

Designed according to the most accepted epidemiological recommendations, ISMAR was aimed to be the first-ever global, quantitative survey to ask separate groups of patients and physicians similar questions to identify differences in attitudes and opinions on the management of AR.

A high percentage of physicians appeared acknowledged about the existence of the most common international guidelines, recognizing their importance in conditioning an optimal disease management. Current guidelines point out the importance of patients’ reported outcomes in decision making. Despite that, the suggestion of guidelines in evaluating patients’ QoL seemed poorly followed, with an apparent low trust in their usefulness for treatment decisions. However, this is probably due to the time consumed in filling this type of questionnaire in a real clinical life. Some physicians paid attention to sleep disturbance provoked by AR.

Concerning the diagnostic approach, the clinical history appeared the most common criteria in categorizing patients on the basis of symptoms severity. The use of other diagnostic instruments, like questionnaires and

---

**Figure 5** Patients’ preferences regarding treatment for rhinitis [Number and percentage of patients]. Only percentages superior to 8 are mentioned. s.c.: subcutaneous.
visual analogue scales appears as unsatisfactory. The number of patients undergoing allergy testing after a diagnosis of nasal complaint was low (38.3%), probably affecting an optimal framing of the respiratory condition. This may be one the reasons for the observed low use of allergen-specific immunotherapy, despite the existing clinical evidence, as well as the no availability of allergen extracts in all participating countries.

As expected house dust mites and pollens were the most common causes of sensitization.

Pharmacotherapy recommendations of guidelines were generally implemented. Most of patients were already receiving treatment at the moment of the visit, mainly oral antihistamines, intranasal corticosteroids and decongestants, which were considered safe and effective by both, patients and physicians, particularly preferred through oral and nasal route of administration.

The typical patient from the surveyed countries referring to medical assessment with a nasal complaint was a non-smoker subject with mild to moderate persistent symptoms, mainly bothered by nasal congestion. This patient is likely able to interpret the causative factors and mentions a significant impairment of his/her QoL, social activities, work or school performances. As expected, patients presented comorbidities, mainly sinusitis or asthma.

A similar survey conducted in the USA among 447 patients with AR visiting their specialist or primary care physician for routine clinical care, found that a significant proportion of patients had moderate or severe disease (62.6%), persistent symptoms (47.6%) and comorbidities such as, asthma (28.8%) or sinusitis (12.5%). The results of this survey highlight the unmet needs of the many patients recruited in Spain, by primary care physicians and specialists, 77 (87.5%) had AR confirmed by symptoms and skin prick testing, measurement of specific immunoglobulin E, or nasal allergen challenge. Most patients had moderate or severe disease (67.0%), which was assessed in terms of severity and persistence of symptoms, and comorbid conditions such as asthma and anxiety. Nasal and ocular symptoms were reported by 83% of patients, either currently or frequently, and 36.4% of patients reported that these symptoms were moderate or severe. More than half of the patients (59.1%) were using 2 or more medicines to...
manage their AR, and 73.7% of patients taking a non-sedating antihistamine plus an intranasal corticosteroid had moderate or severe disease. Most patients (83.1%) reported some impact from the symptoms of AR on daily activities. The mean (SD) mini RQLQ score was 2.4 (1.4) in patients with mild disease, 2.6 (1.2) in patients with moderate disease, and 3.3 (2.3) in patients with severe disease. In this survey physicians estimated that only a minority of patients had symptoms that were poorly controlled, more than one-third of patients reported that their nasal and ocular symptoms were moderate or severe in nature, and most patients considered that their symptoms had an impact on their daily activities, work/school performance, and sleep patterns. The authors concluded that these differences highlight the need for more objective discussion between patients and physicians on the nature, severity, and impact of symptoms, as well as treatment approaches, and how to obtain maximum benefit from currently available prescription medications [16].

Conclusion
In conclusion, the ISMAR registry provided interesting information regarding the management of rhinitis from a patient and physician points of view as well as on the knowledge of guidelines for an optimal management with many similarities between the participating countries.

Further efforts are required to better manage AR and its comorbidities.

Competing interests
Carlos E. Baena-Cagnani: Has received lecture fees and travel expenses from Sanofi for lectures given at international conferences. Was the main investigator of the present study. Giorgio W Canonica: Has received lecture fees and travel expenses from Sanofi for lectures given at international conferences. Mohamed Zaky Helal: Was the National Coordinator of the study in Egypt. Mario E. Zernotti: COI: Has received lecture fees and travel expenses from Sanofi for lectures at national conferences. Mario Sanchez-Borges: Has received lecture fees and travel expenses from Sanofi for lectures given at international conferences. Fabio Fernandes Morato Castro: COI: Has received lecture fees from Sanofi for lectures given at national conferences. Is member of Scientific Advisory Board of Sanofi and receives fees for that. Was the National coordinator of the study in Brazil. Margarita Munueta Agustes: Is an employee of Sanofi. Aida Lopez-Garcia: Was the National Coordinator of the study in Mexico and received fees for this activity. Faheem A Tadros: COI: Has received lecture fees from Sanofi for lectures given at national conferences. Was the National Coordinator in U.A.E.

Authors’ contributions
MMA and CEB-C conceived and designed the study, prepared protocol and CRF, overlooked and coordinated the study, answered to the questions during the data management, validated the Statistical Analysis Plan, interpreted the data and drafted the manuscript and reviewed the final manuscript. CEB-C was the international coordinator. Other authors were the national coordinators. GWC extensively revised the manuscript. RMG, EC and MEZ participated in the preparation of the study design and in writing and reviewing the manuscript. All authors red the manuscript and gave final approval of the version be published. The study was funded by SANOFI, Antony, France.

Author details
1 Research in Respiratory Medicine, Faculty of Medicine, Catholic University of Cordoba - Argentina, Santa Rosa 381, X 5000 ESG Córdoba, Argentina. 2 Respiratory Diseases & Allergy, University of Genoa IRCCS AO Ulster San Martino-IST, Genoa, Italy. 3 Oto-Rhino-Laryngology, Faculty of Medicine, Ain Shams University, Ahmed Lofty Al-Sayed Street Abbassia, Cairo 11341, Egypt. 4 Ayre Foundation, Head, Research & Education, Piedrabuena 702 (A4400DSD) Salta, Argentina. 5 Universidad Católica de Córdoba, Córdoba, Argentina. 6 Clinical Immunology, Faculty of Medicine, Central University of Venezuela, Clinica El Avila 6a Transversal de Urbanización Altamira, Caracas 1060, Venezuela. 7 Universidad de São Paulo, Faculdade de Medicina da Universidade de São Paulo, 24 Departamento de Clinica Médica. Av. Dr. Enéas de Carvalho Aguiar, 155 Cerqueira Cesar, Sao Paulo, SP, Brasil. 8 Medical Director Consumer Health Care Division, Allergy Department, Sanofi, 9 Avenue Romain Rolland, Paris 75014, France. 9 Pediatric Allergy & Immunology Department, Hospital Universitario de Puebla, 25 poniente y 13 sur Centro 3, Puebla CP 72220, México. 10 ENT Consultant, Al Zahra Hospital, P O Box 3499, Sharjah, United Arab Emirates.

Received: 10 April 2014 Accepted: 21 January 2015

References
1. Pawankar R, Canonica GW, ST Holgate ST, Lockey RF, Blaiss M. WAO White Book on Allergy. Update 2013. 2013. http://www.worldallergy.org/UserFiles/file/WhiteBook-2013-v8.pdf. Accessed November 2014.
2. Baena-Cagnani CE, Gómez RM. Is the Prevalence of Allergy Continuously Increasing? In Allergy Frontiers: Epigenetics, Allergens and Risk Factors. Volume 1. Edited by Pawankar R, Holgate ST, Rosenwasser LJ. Tokyo, Japan: Springer; 2009:17–31.
3. Galassi C, De Sario M, Biggeri A, Bisanti L, Chellini E, Ciccone G, et al. Changes in prevalence of asthma and allergies among children and adolescents in Italy; 1994–2002. Pediatrics. 2006;117:34–42.
4. Meltzer EO, Gross GN, Kariel R, Storms WW. Allergic rhinitis substantially impacts patient quality of life. findings from the Nasal Allergy Survey Assessing Limitations. J Fam Pract. 2012;61 Suppl 2:25–10.
5. Blais M, Allergic rhinoconjunctivitis: burden of disease. Allergy Asthma Proc. 2007;28:393–7.
6. Blais M, Pediatric allergic rhinitis: physical and mental complications. Allergy Asthma Proc. 2008;29:1–6.
7. Petersen KD, Gyrd-Hansen D, Dahl R. Heath-Economic Analyses of subcutaneous Specific Immunotherapy for grass pollen and mite allergy. Allergol Immunopathol. 2005;33 Suppl 6:296–302.
8. Bouzquet J, Khaltiaev N, Cruz AA, Denburg J, Fokkens WJ, Topias A, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA (2) LEN and AllerGen). Allergy. 2008;63 Suppl 86:8–160.
9. Baizendi I, Braidio F, Bonini M, Compalati E, Canonica GW. Why do doctors and patients not follow guidelines? Curr Opin Allergy Clin Immunol. 2009;9:28–33.
10. Storms W, Meltzer EO, Nathan RA, Selner JC. Allergic rhinitis: the patient’s perspective. J Allergy Clin Immunol. 1997;99:582–8.
11. Marples BU, Poynter JA, Patel AA, Fineman SM, Fromer L, Krouse JH, et al. Keys to successful management of patients with allergic rhinitis: focus on patient confidence, compliance, and satisfaction. Otolaryngol Head Neck Surg. 2007;136 Suppl 6:107–24.
12. Ciprandi G, Incontrova C, Scarati S, Puccinelli P, Soffa S, Frati F, et al. Patient-related factors in rhinitis and asthma: the satisfaction with allergy treatment survey. Curr Med Res Opin. 2011;27:1005–11.
13. Schatz M. A Survey of the burden of allergic rhinitis in the USA. Allergy. 2007;62 Suppl 85:9–16.
14. Demoly P, Gonzalez V, Utrinelli R, Albert FA. Spreading and impact of the World Health Organization’s Allergic Rhinitis and its impact on asthma guidelines in everyday medical practice in France. Eanni survey. Clin Exp Allergy. 2008;38:1803–7.
15. Valovirta E, Mynshe SE, Falkonen S. The Voice of the Patients: Allergic Rhinitis is not a Trivial Disease. Curr Opin Allergy Clin Immunol. 2008;8:1–9.
16. Mullol J, A Survey of the Burden of Allergic Rhinitis in Spain. J Investig Allergol Clin Immunol. 2009;19:27–34.